Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer
Guillermo Villacampa, Nadine Tung, Sònia Pernas, Laia Paré, Coralia Bueno, Isabel Echavarría, Sara López‐Tarruella, Marta Roche-Molina, Marı́a del Monte-Millán, Mercedes Marín‐Aguilera, Fara Brasó‐Maristany, A.G. Waks, Tomás Pascual, Olga Martínez‐Sáez, Ana Vivancos, PierFranco Conte, Valentina Guarneri, Maria Vittoria Dieci, Gaia Griguolo, Javier Cortés, Antonio Llombart‐Cussac, Montserrat Muñoz-Mateu, María Vidal, Bárbara Adamo, Antonio C. Wolff, A. DeMichele, Patricia Villagrasa, Joel S. Parker, Charles M. Perou, Aranzazu Fernández-Martínez, Lisa A. Carey, Elizabeth A. Mittendorf, Miguel Martín, Aleix Prat, Sara M. Tolaney
Topics & Concepts
MedicineTrastuzumabLapatinibInternal medicinePertuzumabOncologyBreast cancerTaxaneConfidence intervalNeoadjuvant therapyOdds ratioChemotherapyCancerProportional hazards modelGastroenterologyHER2/EGFR in Cancer ResearchBreast Cancer Treatment StudiesAdvanced Breast Cancer Therapies